Intra-Cellular Therapies
ITCI
$72.37
Share price
0.51%
Change (1 day)
15.26%
Change (1 year)
Categories
EPS for Intra-Cellular Therapies (ITCI)
EPS in 2023 (TTM): -$1.61
According to Intra-Cellular Therapies's latest financial reports the company's current EPS (TTM) is -$1.61. In 2022 the company made an earnings per share (EPS) of -$2.72 an increase over its 2021 EPS that were of -$3.50.
EPS history for Intra-Cellular Therapies from 2014 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | -$1.61 | -40.81% |
| 2022 | -$2.72 | -22.29% |
| 2021 | -$3.50 | 8.02% |
| 2020 | -$3.24 | 20.9% |
| 2019 | -$2.68 | -5.63% |
| 2018 | -$2.84 | 33.96% |
| 2017 | -$2.12 | -21.19% |
| 2016 | -$2.69 | -7.56% |
| 2015 | -$2.91 | 174.53% |
| 2014 | -$1.06 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | -$2.14 | 32.92% | 🇺🇸 USA |
 MediciNova MNOV | -$0.25 | -84.47% | 🇺🇸 USA |
 Curis CRIS | -$10.00 | 521.12% | 🇺🇸 USA |